Figure 2From: Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib Progression free survival of sunitinib treatment. The median progression free survival (PFS) with sunitinib is shown by Kaplan-Meier estimate (median 249 days).Back to article page